Tapinarof Cream 1% Once Daily: Significant Efficacy in the Treatment of Atopic Dermatitis in Two Pivotal Phase 3 Trials in Adults and Children Down to 2 Years of Age

Main Article Content

Jonathan I. Silverberg
Lawrence F. Eichenfield
Adelaide A. Hebert
Eric Simpson
Linda Stein Gold
Robert Bissonnette
Kim A. Papp
John Browning
Pearl Kwong
Neil J. Korman
Philip M. Brown
David S. Rubenstein
Stephen C. Piscitelli
Matthew C. Somerville
Anna Tallman
Leon Kircik


atopic dermatitis, eczema, tapinarof cream 1% once daily, efficacy, safety, AhR agonist


1. Weidinger S, et al. Lancet. 2016;387:1109–1122.

2. Bieber T. N Engl J Med. 2008;358:1483–1494.

3. Carroll CL, et al. Pediatr Dermatol. 2005;22:192–199.

4. Lewis-Jones S. Int J Clin Pract. 2006;60:984–992.

5. Nygaard U, et al. Dermatology. 2017;233:333–343.

6. Wu JJ, et al. J Eur Acad Dermatol Venereol. 2016;30:1115–1119.

7. Menter A, et al. J Am Acad Dermatol. 2011;65:137–174.

8. Goh MS, et al. Med J Aust. 2022;216:587–9311.

9. Sideris N, et al. J Clin Med. 2022;11:4974.

10. Dermavant Sciences. VTAMA (tapinarof) cream, 1%: US prescribing information. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215272s000lbl.pdf. Accessed September 2023.

11. Lebwohl MG, et al. N Engl J Med. 2021;385:2219–2229.

12. Strober B, et al. J Am Acad Dermatol. 2022;87:800–806.

13. Pepper J, et al. J Am Acad Dermatol. 2019;80:89–98.e3.

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>